Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | GRM5 | P41594 | 5/20 | 0.64 |
| ▸ | BCHE | P06276 | 8/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13676941 | 0.94 | GRM5 (0.72) | THRBGRM5BCHE | |
| SCHEMBL13676943 | 0.91 | GRM5 (0.62) | THRBGRM5BCHE | |
| SCHEMBL8239115 | 0.88 | THRB (0.66) | THRBGRM5BCHEHTR1AHTR2A | |
| SCHEMBL8232971 | 0.86 | ALDH1A1 (0.69) | THRBGRM5SMN1; SMN2HTR1AHTR2A | |
| SCHEMBL8231576 | 0.86 | GRM5 (0.81) | THRBGRM5SMN1; SMN2HTR1AHTR2A | |
| SCHEMBL3831330 | 0.86 | GRM5 (0.81) | THRBGRM5SMN1; SMN2HTR1AHTR2A | |
| SCHEMBL8240607 | 0.85 | GRM5 (0.65) | THRBGRM5SMN1; SMN2HTR1AHTR2A | |
| SCHEMBL8241041 | 0.83 | THRB (0.64) | THRBGRM5BCHEHTR1AHTR2A | |
| SCHEMBL8238178 | 0.83 | GRM5 (0.72) | THRBGRM5SMN1; SMN2HTR1AHTR2A | |
| SCHEMBL8242932 | 0.82 | THRB (0.68) | THRBGRM5BCHEHTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270371-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | RICHTER GEDEON NYRT. (HU) | 2009-10-29 | — | — | US | claimed |
| EP-1962849-B1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | RICHTER GEDEON NYRT (HU) | 2009-09-30 | — | — | EP | claimed |
| CN-101346141-A | Quinoline derivatives useful in the treatment of MGLUR5 receptor-mediated disorders | RICHTER GEDEON NYRT (HU) | 2009-01-14 | — | — | CN | claimed |
| US-20090270371-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | RICHTER GEDEON NYRT. (HU) | 2009-10-29 | — | — | US | disclosed |
| US-20090270371-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | RICHTER GEDEON NYRT. (HU) | 2009-10-29 | — | — | US | disclosed |
| US-20090270371-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | RICHTER GEDEON NYRT. (HU) | 2009-10-29 | — | — | US | disclosed |
| EP-1962849-B1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | RICHTER GEDEON NYRT (HU) | 2009-09-30 | — | — | EP | disclosed |
| EP-1962849-B1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | RICHTER GEDEON NYRT (HU) | 2009-09-30 | — | — | EP | disclosed |
| CN-101346141-A | Quinoline derivatives useful in the treatment of MGLUR5 receptor-mediated disorders | RICHTER GEDEON NYRT (HU) | 2009-01-14 | — | — | CN | disclosed |
| WO-2007072093-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | RICHTER GEDEON NYRT. (HU) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270371-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | GRM5, GRIK5, GRM1 | THRB 670/4885GRM5 1/4885BCHE 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.